In August 2021 Finfeed changed from a website that covered ASX listed news to a website
that covered a select range of ASX
listed small cap Biotech stocks that we are personally invested in: find out more.
The old Finfeed website, and all of the old articles are kept here for record keeping purposes.VISIT NEW SITE
Archer Exploration & Adelaide University to develop carbon-based biosensor tech
2 minute read
Archer Exploration Limited (ASX:AXE) has today announced that its existing collaboration agreement with The University of Adelaide, for the Australian Research Council Research Hub for Graphene Enabled Industry Transformation, has been redefined.
Under the new term, the collaboration will endeavour to develop and implement graphene and carbon-based materials for use in complex biosensing which can target applications in human health.
Research will explore graphene-based materials for complex biosensing to ideally generate patents with commercial applications — specifically towards the betterment of society — and will combine AXE’s graphite and graphene materials with the Research & Development capability of the university.
This agenda directly aligns with AXE’s vision of developing and integrating advanced materials, specifically in the focus area of human health for the betterment of society.
It’s worth noting that AXE is an early stage play and investors should seek professional financial advice if considering this company for their portfolio.
The global biosensor market is forecast to grow from US$16 billion to US$27 billion from 2016 to 2022; it forms a niche segment of the US$328 billion global biotechnology market. Biosensors have a wide reach, with applications across a broad range of market segments such as medical testing, food toxicity, industrial processes, and environmental and agricultural testing.
The key focus for AXE’s collaboration with Adelaide University will be to develop generic biosensors that can address the largest of these market segments, medical testing; specifically, detection of cholesterol, blood glucose, blood gases, pregnancy, infectious diseases and drugs.
Commenting on the new agreement, AXE CEO Dr Mohammad Choucair said: “This is an exciting repositioning of our materials development focus with the University of Adelaide to target a high value, high growth market for innovative carbon-based technologies. This change is part of our strategy to capture niche segments of the carbon-based material’s market where we have potential competitive advantages as a vertically integrated participant.
“This is the first of our targeted efforts to capture and develop carbon-based solutions with Archer’s graphite and graphene materials through collaboration with The University of Adelaide, and one that offers significant upside potential for Archer.”
The company also stated in today’s announcement that the research activities were expected to result in “the development of all functional elements of a versatile in-vitro electrochemical carbon-based biosensor”. And, if successful, the materials “would be electronically, chemically and structurally tuneable with nanoscale-level optimisation tailored for electrochemical detection of complex biological molecule”.
Such a collaboration could provide AXE with new opportunities and markets to tap into, as it continues its ongoing development of its graphite resources.